MEDIKIT CO.,LTD.

The Group develops, manufactures and sells medical devices, primarily providing devices related to blood vessels and blood. Manufacturing is handled by the consolidated subsidiaries 東郷メディキット㈱ and Medikit Vietnam Co., Ltd., while the Company purchases these products and sells them to users in Japan and overseas. The Group operates as a single segment, with its product portfolio comprising 3 categories: hemodialysis indwelling needles, intravenous indwelling needles and interventional products, plus other products. Its principal products include the “Happy Cath” hemodialysis indwelling needle, including ProFlex-related products, the “Super Cath” intravenous indwelling needle with a safety mechanism, and interventional products such as sheath introducers, catheters and contrast-related equipment. The Group is expanding sales overseas, focusing primarily on the North American, European and Chinese markets. The medium-term management plan, “NEXT 300 Neo,” announced in May 2024, sets indicators and targets through the fiscal year ending March 2029, including sales of ¥29.0–32.0 billion, annual average growth of 5.5–8.5% and an operating margin of approximately 18%. The Group has identified 5 materiality issues: “contributing to society through healthcare,” “creating workplaces where diverse talent can thrive,” “strengthening the management foundation,” “reducing environmental impact” and “contributing to local communities,” and has established 12 specific initiatives under these issues. Its domestic manufacturing facilities are concentrated mainly around Hyuga City, Miyazaki Prefecture, and comprise the Hyuga Plant, Hyuga No. 2 Plant, Hyuga No. 3 Plant, Togo Plant and Sakura Plant. Its overseas locations comprise Medikit Vietnam Co., Ltd. in Vietnam and Medikit Europe GmbH in Germany. For sales and services, メディキット㈱ handles domestic sales, Medikit Europe GmbH handles sales in Europe, and the Sakura distribution warehouse serves as a logistics hub.